Pharmaceutical giant MSD has taken a significant step in advancing patient care by submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its subcutaneous (SC) formulation of the blockbuster immunotherapy drug, Keytruda. This innovative development, achieved through a strategic collaboration with South Korean biotech firm Alteogen, promises to revolutionize treatment delivery and patient experience.

Keytruda, a cornerstone in cancer immunotherapy, generated a staggering 34 trillion KRW in global sales in 2023, solidifying its position as a leading treatment for various solid tumors. However, with patent expiration looming in 2028, MSD has proactively pursued the development of the SC formulation to extend its market exclusivity and enhance patient convenience.

The SC formulation offers several advantages over the traditional intravenous (IV) administration. Patients can expect a more comfortable and efficient treatment process, with reduced side effects and shorter administration times. This advancement not only improves quality of life but also potentially extends the drug's patent life.

Alteogen's role in this groundbreaking development is pivotal. Through their collaborative agreement with MSD, Alteogen's proprietary technology has enabled the successful formulation of Keytruda SC. If the FDA grants approval, Alteogen stands to gain substantial milestone payments and ongoing royalties, significantly bolstering its financial growth. According to analysis from Shinhan Securities, potential royalties could range from 600 billion KRW to 1 trillion KRW, based on estimated annual Keytruda sales of 40 trillion KRW.

MSD's aggressive timeline indicates a strong push for approval and commercialization within the year. This move underscores the company's commitment to innovation and patient-centric solutions.

Beyond the Keytruda SC project, Alteogen is actively expanding its partnerships, securing agreements with companies like Daiichi Sankyo for Enhertu SC, Sandoz for SC biosimilars, and other undisclosed projects. These collaborations highlight Alteogen's growing influence in the development of SC formulations, positioning the company as a key player in the future of drug delivery.

This FDA filing marks a significant milestone for both MSD and Alteogen, signaling a new era of enhanced patient care and strategic biotech partnerships.